Novel Risk Loci Identified in a Genome-Wide Association Study of Urolithiasis in a Japanese Population.


Journal

Journal of the American Society of Nephrology : JASN
ISSN: 1533-3450
Titre abrégé: J Am Soc Nephrol
Pays: United States
ID NLM: 9013836

Informations de publication

Date de publication:
05 2019
Historique:
received: 21 10 2018
accepted: 08 02 2019
pubmed: 13 4 2019
medline: 28 2 2020
entrez: 13 4 2019
Statut: ppublish

Résumé

A family history of urolithiasis is associated with a more than doubling of urolithiasis risk, and a twin study estimating 56% heritability of the condition suggests a pivotal role for host genetic factors. However, previous genome-wide association studies (GWAS) have identified only six risk-related loci. To identify novel urolithiasis-related loci in the Japanese population, we performed a large-scale GWAS of 11,130 cases and 187,639 controls, followed by a replication analysis of 2289 cases and 3817 controls. Diagnosis of urolithiasis was confirmed either by a clinician or using medical records or self-report. We also assessed the association of urolithiasis loci with 16 quantitative traits, including metabolic, kidney-related, and electrolyte traits (such as body mass index, lipid storage, eGFR, serum uric acid, and serum calcium), using up to 160,000 samples from BioBank Japan. The analysis identified 14 significant loci, including nine novel loci. Ten regions showed a significant association with at least one quantitative trait, including metabolic, kidney-related, and electrolyte traits, suggesting a common genetic basis for urolithiasis and these quantitative traits. Four novel loci were related to metabolic traits, obesity, hypertriglyceridemia, or hyperuricemia. The remaining ten loci were associated with kidney- or electrolyte-related traits; these may affect crystallization. Weighted genetic risk score analysis indicated that the highest risk group (top 20%) showed an odds ratio of 1.71 (95% confidence interval, 1.42 to 2.06) - 2.13 (95% confidence interval, 2.00 to 2.27) compared with the reference group (bottom 20%). Our findings provide evidence that host genetic factors related to regulation of metabolic and crystallization pathways contribute to the development of urolithiasis.

Sections du résumé

BACKGROUND
A family history of urolithiasis is associated with a more than doubling of urolithiasis risk, and a twin study estimating 56% heritability of the condition suggests a pivotal role for host genetic factors. However, previous genome-wide association studies (GWAS) have identified only six risk-related loci.
METHODS
To identify novel urolithiasis-related loci in the Japanese population, we performed a large-scale GWAS of 11,130 cases and 187,639 controls, followed by a replication analysis of 2289 cases and 3817 controls. Diagnosis of urolithiasis was confirmed either by a clinician or using medical records or self-report. We also assessed the association of urolithiasis loci with 16 quantitative traits, including metabolic, kidney-related, and electrolyte traits (such as body mass index, lipid storage, eGFR, serum uric acid, and serum calcium), using up to 160,000 samples from BioBank Japan.
RESULTS
The analysis identified 14 significant loci, including nine novel loci. Ten regions showed a significant association with at least one quantitative trait, including metabolic, kidney-related, and electrolyte traits, suggesting a common genetic basis for urolithiasis and these quantitative traits. Four novel loci were related to metabolic traits, obesity, hypertriglyceridemia, or hyperuricemia. The remaining ten loci were associated with kidney- or electrolyte-related traits; these may affect crystallization. Weighted genetic risk score analysis indicated that the highest risk group (top 20%) showed an odds ratio of 1.71 (95% confidence interval, 1.42 to 2.06) - 2.13 (95% confidence interval, 2.00 to 2.27) compared with the reference group (bottom 20%).
CONCLUSIONS
Our findings provide evidence that host genetic factors related to regulation of metabolic and crystallization pathways contribute to the development of urolithiasis.

Identifiants

pubmed: 30975718
pii: ASN.2018090942
doi: 10.1681/ASN.2018090942
pmc: PMC6493984
doi:

Substances chimiques

Uric Acid 268B43MJ25
Calcium SY7Q814VUP

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

855-864

Subventions

Organisme : NIDDK NIH HHS
ID : R01 DK115727
Pays : United States

Informations de copyright

Copyright © 2019 by the American Society of Nephrology.

Références

Kidney Int. 1999 Jun;55(6):2397-406
pubmed: 10354288
Urolithiasis. 2014 Oct;42(5):379-85
pubmed: 25081328
Cell Tissue Res. 2008 Sep;333(3):427-38
pubmed: 18663477
JAMA. 2005 Jan 26;293(4):455-62
pubmed: 15671430
Genet Epidemiol. 2010 Dec;34(8):816-34
pubmed: 21058334
Mol Urol. 2001 Spring;5(1):1-5
pubmed: 11689144
J Clin Gastroenterol. 1982 Feb;4(1):75-86
pubmed: 7042805
Eur Urol. 2000 Mar;37(3):339-44
pubmed: 10720863
Am J Kidney Dis. 2017 Aug;70(2):173-181
pubmed: 28410765
J Am Soc Nephrol. 1997 Oct;8(10):1568-73
pubmed: 9335385
PLoS Genet. 2012;8(3):e1002541
pubmed: 22396660
Pflugers Arch. 2017 Jan;469(1):91-103
pubmed: 27915449
N Engl J Med. 2002 Sep 26;347(13):983-91
pubmed: 12324554
Biochem J. 2005 Nov 15;392(Pt 1):75-81
pubmed: 16029167
Jpn J Clin Oncol. 2014 Sep;44(9):777-82
pubmed: 25104790
Kidney Int. 2005 Mar;67(3):1053-61
pubmed: 15698445
Endocrinology. 2006 Apr;147(4):1685-96
pubmed: 16373417
Nat Genet. 2017 Oct;49(10):1458-1467
pubmed: 28892062
Nat Genet. 2019 Mar;51(3):470-480
pubmed: 30692682
Exp Physiol. 2008 Jan;93(1):43-9
pubmed: 17911353
Diabetes Care. 1996 May;19(5):414-8
pubmed: 8732701
Urology. 2008 Feb;71(2):209-13
pubmed: 18308085
IARC Sci Publ. 1987;(82):1-406
pubmed: 3329634
N Engl J Med. 2008 Oct 23;359(17):1811-21
pubmed: 18946066
Eur Urol. 2001 Oct;40(4):362-71
pubmed: 11713390
J Nephrol. 2010 Nov-Dec;23 Suppl 16:S165-9
pubmed: 21170875
J Epidemiol. 2016 Sep 5;26(9):493-511
pubmed: 27374138
Nat Commun. 2015 May 13;6:7041
pubmed: 25967671
J Epidemiol. 2017 Mar;27(3S):S2-S8
pubmed: 28189464
Genet Epidemiol. 2008 May;32(4):381-5
pubmed: 18348202
J Epidemiol. 2017 Mar;27(3S):S9-S21
pubmed: 28190657
Nature. 2010 Sep 2;467(7311):52-8
pubmed: 20811451
Nat Genet. 2018 Mar;50(3):390-400
pubmed: 29403010
Nat Genet. 2015 Nov;47(11):1236-41
pubmed: 26414676
Eur J Hum Genet. 2011 Jul;19(7):807-12
pubmed: 21407268
N Engl J Med. 2015 Sep 3;373(10):895-907
pubmed: 26287746
Kidney Int. 2005 Sep;68(3):1230-5
pubmed: 16105055
Nat Commun. 2015 Aug 14;6:7975
pubmed: 26272126
Nat Genet. 2004 Apr;36(4):388-93
pubmed: 15052270
Prim Care. 2008 Jun;35(2):215-37, v-vi
pubmed: 18486714
J Hum Genet. 2013 Sep;58(9):588-93
pubmed: 23719187
PLoS Genet. 2009 Jun;5(6):e1000504
pubmed: 19503597
Sci Rep. 2017 Mar 31;7:45766
pubmed: 28361944
J Hum Genet. 2001;46(8):471-7
pubmed: 11501945
Am J Kidney Dis. 2013 Jun;61(6):923-9
pubmed: 23433467
Am J Kidney Dis. 2011 Sep;58(3):383-8
pubmed: 21620546
Eur Urol. 2012 Jul;62(1):160-5
pubmed: 22498635
Bioinformatics. 2010 Sep 1;26(17):2190-1
pubmed: 20616382
Int J Epidemiol. 2012 Feb;41(1):273-86
pubmed: 22253303
Proc Natl Acad Sci U S A. 2004 May 25;101(21):8215-20
pubmed: 15141089
Am J Physiol Renal Physiol. 2007 Feb;292(2):F868-75
pubmed: 16885154
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
Nephrol Dial Transplant. 2009 Mar;24(3):900-6
pubmed: 18835844
PLoS Genet. 2013;9(9):e1003796
pubmed: 24068962
Bioinformatics. 2010 Sep 15;26(18):2336-7
pubmed: 20634204
Diabetologia. 2012 Jan;55(1):114-22
pubmed: 22038520
Nat Genet. 2009 Aug;41(8):926-30
pubmed: 19561606
Nat Commun. 2018 Jan 17;9(1):260
pubmed: 29343764
Bone. 2017 Sep;102:15-25
pubmed: 28238808
Asian Pac J Cancer Prev. 2007 Apr-Jun;8(2):317-23
pubmed: 17696755
Am J Kidney Dis. 2008 May;51(5):741-7
pubmed: 18436084
Am J Hum Genet. 2017 Aug 3;101(2):227-238
pubmed: 28757204
Hum Mol Genet. 2009 Nov 1;18(21):4081-8
pubmed: 19643913
Nat Genet. 2013 Feb;45(2):145-54
pubmed: 23263486
Kidney Int. 2002 Oct;62(4):1136-42
pubmed: 12234283

Auteurs

Chizu Tanikawa (C)

Laboratory of Genome Technology, Human Genome Center.

Yoichiro Kamatani (Y)

Division of Genomic Medicine, RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan.

Chikashi Terao (C)

Division of Genomic Medicine, RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan.

Masayuki Usami (M)

Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Atsushi Takahashi (A)

Division of Genomic Medicine, RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan.
Department of Genomic Medicine, Research Institute, National Cerebral and Cardiovascular Center, Osaka, Japan.

Yukihide Momozawa (Y)

Division of Genomic Medicine, RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan.

Kichiya Suzuki (K)

Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.

Soichi Ogishima (S)

Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.

Atsushi Shimizu (A)

Iwate Tohoku Medical Megabank Organization, Iwate Medical University, Iwate, Japan.

Mamoru Satoh (M)

Iwate Tohoku Medical Megabank Organization, Iwate Medical University, Iwate, Japan.

Keitaro Matsuo (K)

Division of Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan.
Department of Epidemiology and.

Haruo Mikami (H)

Cancer Prevention Center, Chiba Cancer Center Research Institute, Chiba, Japan.

Mariko Naito (M)

Department of Preventive Medicine, Nagoya University Graduate School of Medicine, Aichi, Japan.
Department of Oral Epidemiology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

Kenji Wakai (K)

Department of Preventive Medicine, Nagoya University Graduate School of Medicine, Aichi, Japan.

Taiki Yamaji (T)

Division of Epidemiology and.

Norie Sawada (N)

Division of Epidemiology and.

Motoki Iwasaki (M)

Division of Epidemiology and.

Shoichiro Tsugane (S)

Center for Public Health Sciences, National Cancer Center, Tokyo, Japan; and.

Kenjiro Kohri (K)

Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Alan S L Yu (ASL)

Division of Nephrology and Hypertension and.
The Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas.

Takahiro Yasui (T)

Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Yoshinori Murakami (Y)

Division of Molecular Pathology, Institute of Medical Science, and.

Michiaki Kubo (M)

Division of Genomic Medicine, RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan.

Koichi Matsuda (K)

Laboratory of Clinical Genome Sequencing, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, University of Tokyo, Tokyo, Japan; kmatsuda@edu.k.u-tokyo.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH